lemaitre vascular inc - LMAT

LMAT

Close Chg Chg %
79.59 -0.16 -0.20%

Open Market

79.43

-0.16 (0.20%)

Volume: 41.20K

Last Updated:

Sep 9, 2026, 11:50 AM EDT

Company Overview: lemaitre vascular inc - LMAT

LMAT Key Data

Open

$79.11

Day Range

78.84 - 79.72

52 Week Range

78.27 - 118.01

Market Cap

$1.84B

Shares Outstanding

22.87M

Public Float

21.29M

Beta

0.49

Rev. Per Employee

N/A

P/E Ratio

28.74

EPS

$2.89

Yield

119.36%

Dividend

$0.25

EX-DIVIDEND DATE

Aug 20, 2026

SHORT INTEREST

N/A

AVERAGE VOLUME

325.12K

 

LMAT Performance

1 Week
 
-1.34%
 
1 Month
 
-2.28%
 
3 Months
 
-13.45%
 
1 Year
 
-13.76%
 
5 Years
 
34.78%
 

LMAT Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 8
Full Ratings ➔

About lemaitre vascular inc - LMAT

LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company focuses on the design, marketing, sales, service, and technical support of medical devices and implants for the treatment of peripheral vascular disease. Its products include balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy. The company was founded by George D. LeMaitre on November 28, 1983 and is headquartered in Burlington, MA.

LMAT At a Glance

LeMaitre Vascular, Inc.
63 Second Avenue
Burlington, Massachusetts 01803
Phone 1-781-221-2266 Revenue 249.60M
Industry Medical Specialties Net Income 57.73M
Sector Health Technology 2025 Sales Growth 13.526%
Fiscal Year-end 12 / 2026 Employees 655
View SEC Filings

LMAT Valuation

P/E Current 28.739
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 32.208
Price to Sales Ratio 7.45
Price to Book Ratio 4.693
Price to Cash Flow Ratio 22.89
Enterprise Value to EBITDA 21.525
Enterprise Value to Sales 6.755
Total Debt to Enterprise Value 0.11

LMAT Efficiency

Revenue/Employee 381,071.756
Income Per Employee 88,143.511
Receivables Turnover 7.426
Total Asset Turnover 0.428

LMAT Liquidity

Current Ratio 12.556
Quick Ratio 10.952
Cash Ratio 9.887

LMAT Profitability

Gross Margin 69.268
Operating Margin 27.208
Pretax Margin 30.122
Net Margin 23.13
Return on Assets 9.89
Return on Equity 15.80
Return on Total Capital 9.969
Return on Invested Capital 10.531

LMAT Capital Structure

Total Debt to Total Equity 47.163
Total Debt to Total Capital 32.048
Total Debt to Total Assets 30.144
Long-Term Debt to Equity 46.414
Long-Term Debt to Total Capital 31.54
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Lemaitre Vascular Inc - LMAT

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
161.65M 193.48M 219.86M 249.60M
Sales Growth
+4.68% +19.69% +13.63% +13.53%
Cost of Goods Sold (COGS) incl D&A
62.94M 72.53M 74.75M 76.71M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
9.43M 9.52M 9.61M 10.42M
Depreciation
3.25M 3.42M 3.82M 4.77M
Amortization of Intangibles
6.18M 6.09M 5.79M 5.64M
COGS Growth
+6.25% +15.24% +3.06% +2.62%
Gross Income
98.71M 120.96M 145.12M 172.90M
Gross Income Growth
+3.70% +22.53% +19.97% +19.14%
Gross Profit Margin
+61.07% +62.52% +66.00% +69.27%
2022 2023 2024 2025 5-year trend
SG&A Expense
68.93M 83.88M 92.73M 104.98M
Research & Development
13.29M 16.97M 15.65M 14.14M
Other SG&A
55.64M 66.91M 77.08M 90.84M
SGA Growth
+17.30% +21.68% +10.55% +13.22%
Other Operating Expense
- - - -
-
Unusual Expense
- 2.95M 370.00K 134.00K
EBIT after Unusual Expense
26.83M 36.71M 52.26M 67.91M
Non Operating Income/Expense
661.00K 2.76M 4.82M 12.46M
Non-Operating Interest Income
986.00K 3.08M 4.95M 13.09M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - 205.00K 5.18M
-
Interest Expense Growth
- - -100.00% +2,428.78%
-
Gross Interest Expense
- - 205.00K 5.18M
-
Interest Capitalized
- - - -
-
Pretax Income
27.49M 39.48M 56.88M 75.18M
Pretax Income Growth
-19.82% +43.60% +44.08% +32.19%
Pretax Margin
+17.01% +20.40% +25.87% +30.12%
Income Tax
6.85M 9.37M 12.84M 17.45M
Income Tax - Current - Domestic
6.00M 7.50M 12.15M 13.70M
Income Tax - Current - Foreign
1.03M 1.08M 1.14M 1.44M
Income Tax - Deferred - Domestic
(227.00K) 738.00K (457.00K) 2.26M
Income Tax - Deferred - Foreign
45.00K 45.00K 6.00K 51.00K
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
20.64M 30.11M 44.04M 57.73M
Minority Interest Expense
- - - -
-
Net Income
20.64M 30.11M 44.04M 57.73M
Net Income Growth
-23.31% +45.89% +46.28% +31.10%
Net Margin Growth
+12.77% +15.56% +20.03% +23.13%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
20.64M 30.11M 44.04M 57.73M
Preferred Dividends
- - - -
-
Net Income Available to Common
20.64M 30.11M 44.04M 57.73M
EPS (Basic)
0.9391 1.355 1.9614 2.5503
EPS (Basic) Growth
-26.16% +44.29% +44.75% +30.02%
Basic Shares Outstanding
21.98M 22.22M 22.45M 22.64M
EPS (Diluted)
0.9308 1.3426 1.9333 2.518
EPS (Diluted) Growth
-25.71% +44.24% +44.00% +30.24%
Diluted Shares Outstanding
22.17M 22.42M 22.78M 22.93M
EBITDA
39.22M 46.60M 62.00M 78.33M
EBITDA Growth
-14.56% +18.82% +33.05% +26.34%
EBITDA Margin
+24.26% +24.08% +28.20% +31.38%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 110.00
Number of Ratings 8 Current Quarters Estimate 0.686
FY Report Date 09 / 2026 Current Year's Estimate 2.873
Last Quarter’s Earnings 0.74 Median PE on CY Estimate N/A
Year Ago Earnings 2.52 Next Fiscal Year Estimate 3.179
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 8 8 8 8
Mean Estimate 0.69 0.78 2.87 3.18
High Estimates 0.69 0.79 2.90 3.30
Low Estimate 0.68 0.77 2.83 3.04
Coefficient of Variance 0.75 0.91 0.87 2.30

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 4 4 5
OVERWEIGHT 0 0 0
HOLD 4 4 4
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Lemaitre Vascular Inc - LMAT

Date Name Shares Transaction Value
Mar 13, 2026 Dorian LeBlanc Chief Financial Officer 2,400 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 13, 2026 Dorian LeBlanc Chief Financial Officer 2,302 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $109.2 per share 251,378.40
Mar 13, 2026 Dorian LeBlanc Chief Financial Officer 9 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Lemaitre Vascular Inc in the News